Capivasertib

卡匹色替

Report date: 2026/05/15 20:01:45
NMEFirst In Class

Base Information

Drug NameCapivasertib
Drug Alias NameTruqap荃科得TRUQAPAZD-5363
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase AKT1 inhibitorsSerine/threonine-protein kinase AKT2 inhibitorsSerine/threonine-protein kinase AKT3 inhibitors
TargetsSerine/threonine-protein kinase AKT2Serine/threonine-protein kinase AKT3Serine/threonine-protein kinase AKT1
Therapy Area/IndicationsMetastatic breast cancerHormone-Sensitive Prostate NeoplasmsSolid tumours +[37] 
Global Approved IndicationsMetastatic breast cancerHR-positive breast cancerBreast Neoplasms
Approved Indications in ChinaMetastatic breast cancerHR-positive breast cancerBreast Neoplasms
Original Approved Country/TerritoryUnited States
Original Approved Date2023/11/16
Country/TerritoryCzechiaBelgiumBulgaria +[47] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAstex Pharmaceuticals IncCancer Research TechnologyThe Institute Of Cancer Research, London
China Registration ClassN/A

Develop Information

Active CompaniesCancer Hospital Of Chinese Academy Of Medical SciencesAstrazeneca Pharmaceuticals LpAstrazeneca Uk Ltd +[11] 
Inactive CompaniesDana-Farber Cancer InstituteUniversity Of NottinghamThe Institute Of Cancer Research, London
Active IndicationsMetastatic breast cancerHormone-Sensitive Prostate NeoplasmsSolid tumours +[35] 
Inactive IndicationsProstatic Neoplasms, Castration-ResistantNeoplasms

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG